1. Home
  2. ONEG vs KALA Comparison

ONEG vs KALA Comparison

Compare ONEG & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OneConstruction Group Limited Ordinary Shares

ONEG

OneConstruction Group Limited Ordinary Shares

N/A

Current Price

$1.04

Market Cap

16.5M

ML Signal

N/A

Logo KALA BIO Inc.

KALA

KALA BIO Inc.

HOLD

Current Price

$0.58

Market Cap

13.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONEG
KALA
Founded
2021
2009
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.5M
13.3M
IPO Year
2024
2017

Fundamental Metrics

Financial Performance
Metric
ONEG
KALA
Price
$1.04
$0.58
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$31.50
AVG Volume (30 Days)
27.0K
333.3K
Earning Date
01-14-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
67.39
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.72
$0.07
52 Week High
$14.95
$20.58

Technical Indicators

Market Signals
Indicator
ONEG
KALA
Relative Strength Index (RSI) 48.14 32.86
Support Level $1.00 $0.54
Resistance Level $1.06 $0.72
Average True Range (ATR) 0.02 0.10
MACD 0.01 -0.00
Stochastic Oscillator 65.87 11.76

Price Performance

Historical Comparison
ONEG
KALA

About ONEG OneConstruction Group Limited Ordinary Shares

OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. The company is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction projects include performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.

About KALA KALA BIO Inc.

Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Share on Social Networks: